DNER and brain neoplasm: Extensive preclinical work has been performed to determine the potential efficacy of BET in brain tumors. Glioblastoma multiforme (GBM), the most common and aggressive primary malignant brain tumor, bears a dismal prognosis and therefore presents a challenge for development of novel therapeutic strategy. In considering epigenetic proteins and their recent emergence as novel anticancer targets, several studies have looked at BET proteins as potential targets for therapy.